PRF Technologies Ltd. (PRFX)
NASDAQ: PRFX · Real-Time Price · USD
1.510
-0.090 (-5.63%)
At close: Jun 26, 2026, 4:00 PM EDT
1.380
-0.130 (-8.59%)
Pre-market: Jun 29, 2026, 8:28 AM EDT
Company Description
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel.
It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026.
PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
PRF Technologies Ltd.
| Country | Israel |
| Founded | 2007 |
| IPO Date | Sep 1, 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Efraim Cohen-Arazi |
Contact Details
Address: 65 Yigal Alon St. Tel Aviv-Yafo, 6744316 Israel | |
| Phone | 972 3 7177050 |
| Website | painreform.com |
Stock Details
| Ticker Symbol | PRFX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001801834 |
| CUSIP Number | M77798201 |
| ISIN Number | IL0011651580 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Efraim Cohen-Arazi | Interim Chief Executive Officer and Director |
| Dr. Ehud Geller Ph.D. | Executive Chairman |
| Eyal Broder | Chief Financial Officer |
| Dr. Sigal Aviel eMBA, Ph.D. | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2026 | 6-K | Report of foreign issuer |
| Jun 22, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Jun 22, 2026 | SCHEDULE 13G/A | Filing |
| Jun 18, 2026 | 6-K | Report of foreign issuer |
| Jun 16, 2026 | SCHEDULE 13G/A | Filing |
| May 28, 2026 | 6-K | Report of foreign issuer |
| May 26, 2026 | 6-K | Report of foreign issuer |
| May 19, 2026 | EFFECT | Notice of Effectiveness |
| May 19, 2026 | 424B3 | Prospectus |
| May 13, 2026 | F-1 | Registration statement for certain foreign private issuers |